Caption Management’s Atossa Therapeutics ATOS Stock Holding History

Caption Management’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16,000	Closed	-$782K	–	1587
2021 Q3	$782K	Buy	+16,000	New	+$931K	0.01%	1097

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Caption Management's ATOS Position: Q1 2022 in Review

Caption Management sold out of Atossa Therapeutics (ATOS) in Q1 2022, closing a stake of 8 shares.

Caption Management first reported a position in ATOS in Q2 2021 and held it in 3 quarters. The position peaked at $463K in Q3 2021. 83 funds tracked by Wall St. Rank hold ATOS as of Q1 2022.

Caption Management reported no remaining Atossa Therapeutics position as of Q1 2022 after selling out during the quarter.
Caption Management sold 8 Atossa Therapeutics shares in Q1 2022.
Caption Management first reported a position in Atossa Therapeutics in Q2 2021 and held it in 3 quarters.
Caption Management's Atossa Therapeutics position peaked at $463K in Q3 2021.
83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2022.

Based on Caption Management's 13F filing for Q1 2022, filed 13 May 2022.